deucravacitinib vs Fadeucravacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
Reported efficacy
The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)
Result source: NCT04167462
Fadeucravacitinib
Developed by Beijing InnoCare Pharma Tech Co.
NCT06109818 · Phase 2 · completed
The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.
Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)
Result source: NCT06109818
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | Fadeucravacitinib |
|---|---|---|
| PASI 75 | 53% vs 9.4%+43.6 vs placeboNCT036117519 other results
| —Trial running · NCT06842199 |
| PASI 90 | 27% vs 2.7%+24.3 vs placeboNCT036117512 other results
| —Trial running · NCT06842199 |
| PASI 100 | 10.2% vs 1.2%+9 vs placeboNCT036117512 other results
| —Trial running · NCT06842199 |
| sPGA 0/1 | 49.5% vs 8.6%+40.9 vs placeboNCT0361175111 other results
| —Trial running · NCT06842199 |
| DLQI, change | -10.2 vs -2.9−7.3 vs placeboNCT029318384 other results
| —Trial running · NCT06842199 |
PASI 75
- deucravacitinib
- 53% vs 9.4%+43.6 vs placeboNCT03611751
9 other results
- 58.4% vs 12.7% NCT03624127
- 68.8% vs 8.1% NCT04167462
- 53% vs 39.8% NCT03611751
- 58.4% vs 35.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 66.7% vs 6.7% NCT02931838
- 9.1% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 68.9% vs 6.7% NCT02931838
- Fadeucravacitinib
- —Trial running · NCT06842199
PASI 90
- deucravacitinib
- 27% vs 2.7%+24.3 vs placeboNCT03611751
2 other results
- 35.5% vs 4.2% NCT03624127
- 38.2% vs 1.4% NCT04167462
- Fadeucravacitinib
- —Trial running · NCT06842199
PASI 100
- deucravacitinib
- 10.2% vs 1.2%+9 vs placeboNCT03611751
2 other results
- 14.2% vs 0.6% NCT03624127
- 4.2% vs 0% NCT04167462
- Fadeucravacitinib
- —Trial running · NCT06842199
sPGA 0/1
- deucravacitinib
- 49.5% vs 8.6%+40.9 vs placeboNCT03611751
11 other results
- 53.6% vs 7.2% NCT03624127
- 55.6% vs 6.8% NCT04167462
- 49.5% vs 33.9% NCT03611751
- 53.6% vs 32.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 64.4% vs 6.7% NCT02931838
- 20.5% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 75.6% vs 6.7% NCT02931838
- 35.5% vs 8.2% NCT05701995
- 51% vs 4.3% NCT05478499
- Fadeucravacitinib
- —Trial running · NCT06842199
DLQI, change
- deucravacitinib
- -10.2 vs -2.9−7.3 vs placeboNCT02931838
4 other results
- -8.4 vs -2.9 NCT02931838
- -3.8 vs -2.9 NCT02931838
- -6.1 vs -2.9 NCT02931838
- -9.7 vs -2.9 NCT02931838
- Fadeucravacitinib
- —Trial running · NCT06842199
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. deucravacitinib: 4 of 4 rows · Fadeucravacitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib |
|---|---|
| Dropout rate | 0.2%BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy 0%BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 9.6%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 0.8%Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 8.7%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 8.1%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 4.5%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 13.3%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 18.2%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 22.7%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 2.7%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 3.9%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 5.4%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 2.3%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 4.5%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results1.6%BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy 2.9%BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy 2.1%BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy 5.8%BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy —Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy 2.7%BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy 0%BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy 4.9%Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 2.5%Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence 4.3%Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 1%Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 6.8%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 0%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 0%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 10.8% (placebo 11.4%) upper respiratory tract infection 4.9% (placebo 4.3%) diarrhoea 4.7% (placebo 7.5%) NCT03611751 · Phase 3 · monotherapy show 15 more resultsnasopharyngitis 16% (placebo 11.4%) upper respiratory tract infection 8.9% (placebo 4.3%) headache 5.4% (placebo 5.5%) NCT03611751 · Phase 3 · monotherapy nasopharyngitis 6.3% (placebo 4.2%) upper respiratory tract infection 6.3% (placebo 3.6%) headache 4.8% (placebo 3%) NCT03624127 · Phase 3 · monotherapy nasopharyngitis 18.1% (placebo 4.2%) upper respiratory tract infection 9.4% (placebo 3.6%) headache 6.6% (placebo 3%) NCT03624127 · Phase 3 · monotherapy upper respiratory tract infection 17.8% (placebo 18.9%) mouth ulceration 7.5% (placebo 5.4%) nasopharyngitis 6.8% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy psoriasis 11.8% (placebo 2.7%) headache 5.9% (placebo 0%) nasopharyngitis 5.9% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy covid-19 9.7% (placebo 4.1%) upper respiratory tract infection 7.8% (placebo 2%) nasopharyngitis 3.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence acne 7.6% (placebo 4.1%) nasopharyngitis 6.7% (placebo 4.1%) covid-19 5.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.4% (placebo 17.8%) covid-19 12.8% (placebo 8.9%) upper respiratory tract infection 11.7% (placebo 6.7%) NCT05478499 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.5% (placebo 17.8%) upper respiratory tract infection 11.7% (placebo 6.7%) acne 9.7% (placebo 2.2%) NCT05478499 · Phase 4 · registry result, not featured evidence 6 mg QD nasopharyngitis 31.1% acne 9.5% constipation 5.4% NCT03924427 · Phase 3 · registry result, not featured evidence 12 mg QD blood creatine phosphokinase increased 15.9% (placebo 2.2%) acne 9.1% (placebo 0%) diarrhoea 9.1% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 6 mg BID nasopharyngitis 15.6% (placebo 4.4%) blood creatine phosphokinase increased 8.9% (placebo 2.2%) upper respiratory tract infection 8.9% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg BID nasopharyngitis 11.1% (placebo 4.4%) aphthous ulcer 6.7% (placebo 0%) headache 6.7% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QD nasopharyngitis 11.4% (placebo 4.4%) headache 9.1% (placebo 4.4%) psoriasis 6.8% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QOD headache 9.1% (placebo 4.4%) nausea 9.1% (placebo 4.4%) blood immunoglobulin e increased 6.8% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 15 more results
show 13 more results
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 1 more result
+ 11 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · Fadeucravacitinib's landscape